Pro-Dex (PDEX)
NASDAQ:PDEX
Top Page
Pro-Dex
(NASDAQ:PDEX)
Select Model
Select Model
Rating:76Outperform
Price Target:
$58.00
▲(57.78% Upside)
Action:UpgradedDate:04/04/26
The score is driven primarily by strong recent profitability and improving leverage, supported by clear positive technical trend/momentum. The main offsets are volatile cash flow conversion and the added execution risk from the debt-funded acquisition; valuation appears reasonable with a moderate P/E.
Positive Factors
Strong profitability & ROE
Sustained high margins and a very strong TTM ROE indicate durable cost control, favorable product mix and pricing power in its OEM manufacturing niche. These fundamentals support reinvestment, resilience to cyclical dips, and the ability to fund growth or service debt over the medium term.
Negative Factors
Inconsistent cash generation
Volatile operating and free cash flow driven by working-capital swings reduces predictability of internal funding for capex, acquisitions, or buybacks. This inconsistency raises financing risk when absorbing integration costs or supporting ramping customer programs over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong profitability & ROE
Sustained high margins and a very strong TTM ROE indicate durable cost control, favorable product mix and pricing power in its OEM manufacturing niche. These fundamentals support reinvestment, resilience to cyclical dips, and the ability to fund growth or service debt over the medium term.
Read all positive factors
Pro-Dex (PDEX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$157.00M
Dividend YieldN/A
Average Volume (3M)29.60K
Price to Earnings (P/E)14.3
Beta (1Y)0.06
Revenue Growth23.65%
EPS Growth120.84%
CountryUS
Employees146
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.66
Shares Outstanding3,205,985
10 Day Avg. Volume32,852
30 Day Avg. Volume29,604
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.92
Price to Sales (P/S)2.15
P/FCF Ratio-49.00
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue2.36
Enterprise Value/Gross Profit8.33
Enterprise Value/Ebitda9.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pro-Dex Business Overview & Revenue Model
Company Description
Pro-Dex, Inc. (PDEX) is a publicly traded company that specializes in the development and manufacture of innovative products for the medical and industrial sectors. The company focuses primarily on the production of precision-engineered devices an...
How the Company Makes Money
Pro-Dex makes money primarily by providing contract design, development, and manufacturing services for medical device customers, with revenue recognized from the sale of finished powered surgical instruments, instrument systems, and related parts...
Pro-Dex Key Performance Indicators (KPIs)
Any
Revenue by Segment
Highlights revenue from different business segments, revealing which areas are driving growth and which may need strategic adjustments.
Highlights revenue from different business segments, revealing which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyPro-Dex Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
78
Positive
Cash Flow
57
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 72.10M | 66.59M | 53.84M | 46.09M | 42.04M | 42.04M |
| Gross Profit | 20.40M | 19.51M | 14.55M | 12.75M | 13.13M | 13.13M |
| EBITDA | 17.37M | 14.13M | 4.35M | 10.82M | 6.88M | 6.88M |
| Net Income | 11.34M | 8.98M | 2.13M | 7.07M | 4.57M | 4.57M |
Balance Sheet | ||||||
| Total Assets | 62.26M | 61.19M | 52.48M | 51.82M | 49.09M | 49.09M |
| Cash, Cash Equivalents and Short-Term Investments | 8.82M | 7.16M | 6.85M | 4.07M | 1.60M | 1.60M |
| Total Debt | 11.83M | 16.58M | 13.55M | 14.79M | 15.97M | 15.97M |
| Total Liabilities | 20.63M | 24.56M | 21.61M | 20.23M | 23.66M | 23.66M |
| Stockholders Equity | 41.63M | 36.63M | 30.87M | 31.59M | 25.43M | 25.43M |
Cash Flow | ||||||
| Free Cash Flow | 6.12M | -2.93M | 5.22M | 4.49M | -2.52M | -2.52M |
| Operating Cash Flow | 6.46M | -1.68M | 6.20M | 5.46M | -847.00K | -847.00K |
| Investing Cash Flow | 9.51M | -238.00K | -2.23M | -885.00K | -1.24M | -1.24M |
| Financing Cash Flow | -8.08M | -292.00K | -4.27M | -2.49M | -790.00K | -790.00K |
Pro-Dex Technical Analysis
Positive
36.76
Price Trends
44.46
Positive
41.67
Positive
40.49
Positive
Market Momentum
1.37
Positive
53.99
Neutral
40.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PDEX, the sentiment is Positive. The current price of 36.76 is below the 20-day moving average (MA) of 48.82, below the 50-day MA of 44.46, and below the 200-day MA of 40.49, indicating a bullish trend. The MACD of 1.37 indicates Positive momentum. The RSI at 53.99 is Neutral, neither overbought nor oversold. The STOCH value of 40.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PDEX.
Pro-Dex Risk Analysis
Pro-Dex disclosed 24 risk factors in its most recent earnings report. Pro-Dex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pro-Dex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $157.00M | 14.29 | 29.25% | ― | 23.65% | 120.84% | |
56 Neutral | $205.53M | 16.41 | 9.56% | 2.15% | -12.35% | -17.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $194.29M | -101.73 | -21.71% | ― | 22.12% | 69.19% |
* Healthcare Sector Average
PDEX
Pro-Dex
50.87
-10.23
-16.74%
UTMD
Utah Medical Products
64.86
13.04
25.17%
MBOT
Microbot Medical
2.48
0.69
38.55%
KRMD
REPRO-MED Systems
4.37
2.09
91.67%
STSS
Sharps Technology, Inc.
1.63
-3.86
-70.31%
ZJYL
Jin Medical International Ltd.
2.20
-10.20
-82.26%
Pro-Dex Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Pro-Dex Completes Acquisition of Advanced Precision Machining
Positive
Feb 12, 2026
On February 9, 2026, Pro-Dex, Inc. completed the acquisition of Advanced Precision Machining LLC, a Costa Mesa, California-based manufacturer of machined components that serves medical device, aerospace, defense, and U.S. Government customers, mak...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.